- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
England Missed Out on Biosimilar Insulin Glargine Savings, Study Says
Investigators said the English health care system has realized only a sliver of the potential savings potential from biosimilar insulin glargine and that uptake is widely uneven across health care centers.
A study of biosimilar insulin glargine uptake in England found huge missed savings over a 4-year period starting with the reference product’s loss of exclusivity in 2014.
The study, published in the current issue of Diabetes Care, said the savings generated from biosimilar use totaled just $1.1 million and the missed savings amounted to $32.1 million, “indicating that only 3.42% of the potential savings were achieved.”
Investigators also noted a large variation in uptake of insulin glargine biosimilars across Clinical Commissioning Groups (CCGs), which serve to facilitate health care services between patients, physicians, and community groups.
Insulin glargine market shares between these groups ranged from 0% to 53.3% in December 2018, according to the study.
“These results may encourage decision makers in England to promote the use of best-value treatments in primary care and to reevaluate variation across CCGs,” authors of the study wrote.
To conduct the study, investigators collected information on all insulin glargine products prescribed by general practitioners up through December 2018. They then calculated total costs of insulin glargine and uptake rates of biosimilars.
They estimated what it would have cost to have filled all of the prescriptions with the reference product versus the actual cost of biosimilar and reference insulin glargine. The missed savings amount was based on what it would have cost to supply all of the patients with biosimilar forms of the drug.
Investigators described the study as the first to analyze adoption rates for insulin glargine biosimilars in the primary care environment in England and calculate the savings achieved and missed. The reference product that formed the basis for the study was Lantus.
Reference
Agirrezabal I, Sánchez-Iriso E, Mandar K, Cabasés JM. Real-world budget impact of the adoption of insulin glargine biosimilars in primary care in England (2015—2018). Diabetes Care. 2020;43(6):dc192395. doi:10.2337/dc19-2395
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Aflibercept Biosimilar MYL-1701P Provides Equivalence in DME Therapy
November 27th 2024The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME.
